Youth and Opioids: Trends and Treatment

Jennifer Exo, DO Associate Medical Director Hazelden Betty Ford Foundation






Learning Objectives

- Understand national trends in opioid use among youth
- Describe pathways to opioid use including fentanyl in youth
- Discuss medication options for treatment of OUD in youth (MOUD)
- Implement effective preventative and risk mitigation strategies for youth at risk for opioid misuse/abuse



Substance Use in Youth




1 in 7 have ever abused prescription opioids
1 in 14 are currently abusing prescription opioids



Substance Use in Youth

100


 Most youth have issues with other substances before initiating opioid use



Substance use behaviors

 \downarrow initiation of any substance use in youth \downarrow opioid use in youth


Non-prescription Opioid Sources





Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Surveys on Drug Use and Health (NSDUHs), 2013 and 2014.

Opioid Use in Youth





Opioid Use in Youth

Rapidly progressing disease




18-24 months



"Fake" Prescription Opioid Pills

Number of Pills Containing Fentanyl Seized by Law Enforcement in the United States, 2018 – 2021



Estimates based on data reported by the Office of National Drug Control Policy's High Intensity Drug Trafficking Areas program

Reference: JJ Palamar, et al. Drug and Alcohol Dependence. DOI: 10.1016/j.drugalcdep.2022.109398 (2022)


40% of all pills seized contain fentanyl
83% of all illicit opioid pills contain fentanyl




NIH National Institute on Drug Abuse

nida.nih.gov

Opioid Overdose in Youth





 Median monthly overdose deaths among 10-19 yo increased 109%

- 90% opioids (83% illicit fentanyl)
- Deaths related to illicitly manufactured fentanyl increased 182%



Fentanyl Contamination



*FAKE oxycodone M30 tablets containing fentanyl

Assume the pill is fake



Fentanyl-contaminated cocaine



Fentanyl and Youth



- Younger age has been associated with:
 - Seeking fentanyl over less potent opioids
 - Identifying *non-fatal* overdose as primary risk of fentanyl use
 - Difficulty consistently using harm reducing behaviors
 - Perception risk of withdrawal > risk of overdose
 - "Immunity" to overdose

Knowledge of overdose risk factors ≠ behavioral change



Treatment of OUD in Youth

Comfort medications Buprenorphine

Withdrawal management

MOUD Management of comorbid mental health conditions Relapse prevention skills Behavioral interventions

Naloxone distribution and education Overdose recognition and treatment Testing strips Safe spaces to use

Harm Maintenance reduction therapy



MOUD in Youth

- Scientific literature supports use of MOUD in youth
- Multiple scientific medical organizations support use of MOUD



MOUD in Youth

- Dissemination of MOUD hampered by misinformation and prejudice
 - Patients, family, support systems
 - Recovery communities
 - Providers of chemical dependency treatment services
 - Treatment with MOUD precludes patient from participation in services
 - Young adults more likely than adolescents to receive MOUD





MOUD in Youth

- Developmental barriers to uptake of MOUD by youth
 - Sense of invincibility and omnipotence
 - Varying degrees of internal and external motivation
 - Less salience of consequences
 - Stronger salience of burdens of treatment
 - Developmentally normal resistance to parental influence and restrictions





MOUD: Buprenorphine Products

- Goals of treatment:
- 1. Eradication of withdrawal symptoms
- 2. Meaningful reduction in cravings
- 3. Minimal side effects
- SL maintenance dosing range 2-24 mg/day
- Extended-release buprenorphine following stabilization on SL



MOUD: Naltrexone

- Immediate-release (oral) and <u>extended-release (IM)</u> formulations
- Use in adolescents not well characterized
- Generally well-tolerated, no significant adverse safety signals
- Compliance issues:
 - Difficulty tolerating opioid detoxification prior to administration
 - Early enthusiasm followed by waning interest
 - Barriers to follow up visits



MOUD: Methadone

- Safety and effectiveness not established in children <18 years
- Many barriers to use
- Studies demonstrate increased retention in treatment among young adults treated with methadone




MOUD: Length of Treatment

- Optimal length of treatment has not been well established
 - 12 weeks of treatment SL buprenorphine significantly improves outcome vs. early taper
- Discuss potential increased risk of overdose death in first 4 weeks following discontinuation





Harm Reduction





Conclusions

- While most youth do NOT abuse opioids, those that do are at risk of worse outcomes vs. adults
- MOUD should be the standard of care for affected youth
- Best outcomes with longitudinal MOUD + behavioral interventions, mental health support, harm reduction



References

- Clayton HB, et al. Prescription opioid misuse associated with risk behaviors among adolescents. Am J Prev Med 2019;57:533-9.
- Tanz LJ et al. Drug Overdose Deaths Among Persons Aged 10-19 Years United States, July 2019-December 2021. MMWR Morb Mortal Wkly Rep 2022;71:1576-1582.
- Scholl L et al. Opioid-involved overdose deaths United States, 2013-2017. Morb Mortal Wkly Rep 2019;67:1419-1427.
- Gaither JR, et al. National trends in hospitalizations for opioid poisonings among children and adolescents, 1997-2012. JAMA Pediatrics 2016;170:1195-1201.
- Centers for Disease Control and Prevention. 2019 Youth Risk Behavior Survey Questionnaire. Available at <u>www.cdc.gov/yrbs</u>. Accessed on April 6, 2023.
- Partnership for Drug-Free Kids. The 2006 Partnership Attitude Tracking Study. Available at: <u>www.drugfree.org</u>. Accessed on April 6, 2023.
- Kral A et al. Addressing the nation's opioid epidemic: lessons learned from an unsanctioned supervised injection side in the US. Am J Prev Med 2017;53:919-922,
- Peiper NC et al. Fentanyl test strips as an opioid overdose prevention strategy: findings from a syringe service program in southeastern United States. Int J Drug Policy 2019;63:122-128.
- Neira-Leon M et al. Infrequent opioid overdose risk reduction behaviours among young adult heroin users in cities with wide coverage of HIV prevention programmes. Int J Drug Policy 2011;22:16-25.



References

- Calvo M et al. Young people who use drugs engaged in harm reduction programs in New York City: overdose and other risks. Drug Alcohol Depend 2017;178:106-114.
- Morales KB et al. Preference for drugs containing fentanyl from a cross-sectional survey of people who use illicit opioids in three United States cities. Drug Alcohol Depend 2019;204:107547.
- Hadland S et al. Receipt of timely addiction treatment and association of early medication treatment with retention in care among youths with opioid use disorder. JAMA Pediatr. 2018;172:1029-1037.
- Committee on Substance Use and Prevention. Medication-assisted treatment of adolescents with opioid use disorders. Pediatrics 2016;138:e20161893.
- Center for Substance Abuse Treatment. Medications for Opioid Use Disorder: Treatment Improvement Protocol (TIP) Series, No. 63. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2021.
- Minozzi S et al. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database of Systematic Reviews 2011;2:1-45.
- Kampman K et al. American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med 2015;9:358-367.



Q&A Thank You!

